top of page

GSK submits sBLA seeking expanded indication for Flulaval Quadrivalent

GSK has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Flulaval Quadrivalent (Influenza Vaccine).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page